Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer

Yee Lu Tham, Mario S. Verani, Jenny C. Chang

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

One of the newest agents used in the treatment of breast cancer is trastuzumab (Herceptin®), a new recombinant DNA-derived humanized monoclonal antibody against the proto-oncogene, HER-2/neu gene product. However, despite its proven clinical efficacy, serious adverse effects leading to trastuzumab-induced cardiomyopathy have been described in up to 27% of patients receiving combination therapy with anthracyclines [1]. There has been little published on the clinical syndrome of trastuzumab-induced cardiomyopathy. We describe three cases, of both reversible and irreversible cardiomyopathy, associated with the use of this novel and effective agent in HER-2 overexpressing breast cancer.

Original languageEnglish (US)
Pages (from-to)131-134
Number of pages4
JournalBreast Cancer Research and Treatment
Volume74
Issue number2
DOIs
StatePublished - 2002

Keywords

  • Breast cancer
  • Cardiomyopathy
  • Herceptin®
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer'. Together they form a unique fingerprint.

Cite this